EP Patent

EP4455146A2 — Morphic forms of git38 and methods of manufacture thereof

Assigned to Pharmacosmos Holding AS · Expires 2024-10-30 · 2y expired

What this patent protects

This invention provides an unexpectedly stable, highly crystalline form of the di-HCl salt of 2'-((5-(4-isopropylpiperazin-1-yl)pyridin-2-yl)amino)-7',8'-dihydro-6'H-spiro[cyclohexane-1,9'-pyrazino[1',2':1,5]pyrrolo[2,3-d]pyrimidin]-6'-one for advantageous therapeutic pharmaceuti…

USPTO Abstract

This invention provides an unexpectedly stable, highly crystalline form of the di-HCl salt of 2'-((5-(4-isopropylpiperazin-1-yl)pyridin-2-yl)amino)-7',8'-dihydro-6'H-spiro[cyclohexane-1,9'-pyrazino[1',2':1,5]pyrrolo[2,3-d]pyrimidin]-6'-one for advantageous therapeutic pharmaceutical efficacy and dosage form stability.

Drugs covered by this patent

Patent Metadata

Patent number
EP4455146A2
Jurisdiction
EP
Classification
Expires
2024-10-30
Drug substance claim
No
Drug product claim
No
Assignee
Pharmacosmos Holding AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.